1. Home
  2. XPL vs TCRX Comparison

XPL vs TCRX Comparison

Compare XPL & TCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Solitario Resources Corp.

XPL

Solitario Resources Corp.

HOLD

Current Price

$0.74

Market Cap

64.6M

ML Signal

HOLD

Logo TScan Therapeutics Inc.

TCRX

TScan Therapeutics Inc.

HOLD

Current Price

$1.15

Market Cap

64.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
XPL
TCRX
Founded
1984
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Precious Metals
Biotechnology: Pharmaceutical Preparations
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
64.6M
64.1M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
XPL
TCRX
Price
$0.74
$1.15
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
7
Target Price
$1.20
$8.50
AVG Volume (30 Days)
228.6K
597.2K
Earning Date
10-31-2025
03-04-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$8,423,000.00
Revenue This Year
N/A
$286.83
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.54
$0.88
52 Week High
$0.90
$2.85

Technical Indicators

Market Signals
Indicator
XPL
TCRX
Relative Strength Index (RSI) N/A 53.33
Support Level N/A $1.13
Resistance Level N/A $1.27
Average True Range (ATR) 0.00 0.08
MACD 0.00 0.02
Stochastic Oscillator 0.00 55.74

Price Performance

Historical Comparison
XPL
TCRX

About XPL Solitario Resources Corp.

Solitario Resources Corp is exploration company engaging in acquiring, exploring, and developing zinc properties and other precious metals in safe jurisdictions in North and South America. It has joint venture interests in large, high-grade zinc development projects. The Florida Canyon Zinc Project in Peru is a development asset held jointly with Nexa Resources S.A., Golden Crest Project in South Dakota and the Lik Zinc Project represents a large-tonnage, high-grade development project in Alaska in partnership with Teck Resources. In addition, the company has an additional portfolio of exploration properties and royalties in the Americas.

About TCRX TScan Therapeutics Inc.

TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.

Share on Social Networks: